White blood cells (WBCs) play vital roles in host defense. Recently, increasing interest has been di rected toward the question of whether WBCs. particu larly polymorphonuclear leukocytes. could also act as mediators of secondary brain damage in the setting of focal and global cerebral ischemia with and without reper fusion. Considerable insight into the importance of WBC mediated tissue injury has been gained from studies em ploying antileukocyte interventions in experimental cere bral ischemia. The purpose of this article is to survey the different approaches taken to interfere with WBC inflam matory function. Emphasis is laid on a discussion of the efficacy of these interventions. their effects and side ef-
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The behavior of white blood cells (WBCs) and their mobility in physiological and disease states have fascinated biologists for many decades. It was not until the recent investigation of cytoplasmic and cell membrane adhesion molecules that an under standing of the molecular mechanisms underlying margination, adhesion, and emigration of WBCs ����-" " �----� ---"----, "---,�-fects on cerebral and systemic parameters, and the power of evidence they provide for identification of WBCs as important factors in cerebral ischemia. The role of WBCs has been investigated in a great variety of global and focal cerebral ischemia models with and without repert'usion, leading to spmetimes contradictory results, In the light of currently available data, it seems likely that WBCs con tribute to secondary brain damage in the scenario of ex perimental transient focal cerebral ischemia, if the insult is not too severe. Key Words: Cerebral ischemia Leukocytes-Neutrophils-Secondary brain damage White blood cells.
into parenchymal tissue emerged (Granger and Kubes. 1994a; Springer, 1994) , The importance of cellular adhesion molecules for WBC trafficking is now becoming apparent. While initial research fo cused on the vital role of WBCs in host defense, evidence implicating WBCs as mediators of tissue injury in different disease states that had previously not been regarded as "inflammatory" is now accu mulating (Schmid-Schonbein, 1993) , Among these are myocardial infarction, circulatory shock, arte riosclerosis, adult respiratory distress syndrome, diabetic retinopathy, venous and intestinal ulcers, traumatic brain injury, and ischemic stroke (Schmid Schonbein and Granger, 1995) . The role of WBCs, particularly polymorphonu clear leukocytes (PMNLs) and monocytes, in the evolution of necrosis under pathophysiological con ditions has been examined. Experimental studies in the 1960s indicated that reperfusion of ischemic my ocardium resulted in an acceleration of tissue ne crosis (Sommers and Jennings, 1964) , and PMNLs were implicated as participants in "reperfusion in-jury." This notion received support from studies showing that pharmacological induction of neutro penia reduced myocardial infarct size in models of coronary artery occlusion and reperfusion (Romson et al., 1983; Litt et al., 1989) . As a consequence, interest in the role of WBCs in reperfusion injury has intensified dramatically over the last 10 years. Recent reports of clinical improvement with reper fusion strategies in ischemic stroke encourage the search for further therapeutic interventions. In this respect, modulation of WBC function appears as a promising candidate to improve outcome in acute stroke patients.
WBCs

WBC accumulation and tissue injury in acute cerebral lesions
In 1986 Hallenbeck et al. demonstrated signifi cant early PMNL accumulation during the first 4 h after induction of embolic cerebral ischemia in dogs. The authors explained their finding by either increased PMNLIendothelial cell (EC) adhesion or the formation of PMNL aggregates during ischemia! reperfusion (I1R). This report stimulated a wide va riety of experimental studies looking at early post ischemic WBC contribution to brain damage (Ta bles 1-3).
Mechanisms of WBC-mediated tissue injury
WBCs have been implicated in the pathogenesis of focal cerebral I1R microvascular occlusion (Del Zoppo et al., 1991; Mori et al., 1992; , suggesting an element. of the "no-reflow" phenomenon described after global cerebral isch emia by Ames et al. (1968) , as well as in delayed postischemic hypoperfusion (Grogaard et al., 1989; Schiirer et al., 1990a) first described by Snyder et al. (1975) . WBCs may physically plug and obstruct microvessels (Engler et aI., 1983; Schmid Schonbein, 1987; Hatchell et al., 1994) , release va soconstrictive mediators (Lopez et al., 1989; Faraci et aI., 1991; Mugge et al., 1991) , cause dysfunction of the vasoreactivity of cerebral arteries (Akopov et al., 1994) , injure ECs directly, or migrate into the brain tissue where they may damage parenchymal cells through the release of cytotoxic enzymes, free oxygen radicals, and products of the phospholipid cascade (Weiss, 1989; Welbourn et aI., 1991) . PMNLs have recently been identified as the major source of oxygen radicals in reperfusion after focal cerebral ischemia in the rat brain (Matsuo et al., 1995) .
Experiments by Suematsu et al. (1993) provided the first in vivo evidence for intraendothelial oxida tive stress induced by activated WBCs in the rat mesentery. The same group reported that early «90 min) I1R-induced cell death in rat skeletal mus cle was not related to WBC activation. These find ings do not abrogate the potentially harmful effects of WBCs in the central nervous system because dis-ruption of the blood-brain barrier can occur without irreversible endothelial or glial cell death (Granger and Kubes, 1994h; Kurose et aI., 1994) . Subsequent formation of vasogenic brain edema can be detri- mental, leading to increased intracranial pressure (ICP), ischemia, and secondary cell death. This is an important difference between the brain and pe ripheral organs where edema formation does not have such harmful consequences.
Blocking of WBCs and/or WBC function
Probably the most valuable insight into the im portance of WBC-mediated tissue injury in cerebral is chemia has been gained from studies employing antileukocyte interventions in experimental models of cerebral and non cerebral I1R. Efforts have been centered on PMNLs, since these cells are the first to arrive at the ischemic and inflammatory focus, reaching the cerebral parenchyma within hours af ter the insult and peaking between 24 and 72 h (Ward et ai., 1988; Clark et ai., 1993; Garcia et ai., 1993 Garcia et ai., , 1994a Zhang et ai., 1994b) .
The purpose of this article is to survey the differ ent methodological approaches directed at the inhi bition of PMNL-mediated inflammatory function. It will concentrate on interventions used to either re duce the peripheral WBC count or interfere with the capability of WBCs to adhere to the vascular endo thelium, assuming that this represents a key step in the subsequent events leading to enhancement of cerebral tissue injury. In an attempt to evaluate the relative scientific merit of different experimental approaches and findings, emphasis will be placed on the efficacy of these interventions ahd their ef fects and side effects on c erebral and systemic physiological parameters.
PMNL DEPLETION
Antineutrophil serum
Since the early observations of the Russian biol ogist Elie Metchnikoff in 1899, it has been known that "antileukocyte serum" can be prepared by im munizing animals with WBCs from another species. Intravenous administration of antineutrophil serum (ANS) leads to sequestration of PMNLs in the lungs (Sandler et aI., 1987; Grogaard et ai., 1989) . This may be accompanied by acute hemodynamic changes (L. Schiirer, personal communication) and decreased complement activity (Sandler et aI., 1987) . Neutropenia lasting up to 7 days can be in duced by intraperitoneal administration of ANS in rodents (Simpson and Ross, 197 1; Sandler et aI., 1987) . A reduction of circulating PMNLs ranging between 80 and 95% and monocytes up to 50% dur ing the first hours after administration has been re ported (Tables 1 and 2) . ANS also activates circu lating cells, ECs, and tissue macrophages, the neutropenia might therefore reflect a redistribution of PMNLs into the marginated pool (Schmid Schonbein, 1993) . Actually, an absolute reduction of all WBCs to zero does not occur owing to rapid redistribution from bone marrow stores. ANS mediated microvascular trapping of PMNLs in the cerebral circulation might also amplify the injury process and blunt the benefits achieved by PMNL depletion.
ANS has been employed in studies of experimen tal global cerebral ischemia, global forebrain isch emia, and focal permanent cerebral ischemia (Ta bles I and 2). When rats were exposed to ANS prior to 15-min global forebrain ischemia and arterial hy potension, CBF improved early (l h) after the insult (Grogaard et aI., 1989; Schiirer et aI., 1990a) . After a period of 7 days, however, quantitative histology failed to reveal any differences in nerve cell survival between neutropenic animals and untreated con trols (Schiirer et aI., 199 1). In a cardiac arrest model of global cerebral ischemia in dogs, Schott et ai. (1989) reported decreased survival times in ANS treated animals at 24 h as compared with nontreated controls. The latter study has been questioned be cause mortality was high even in the experimental group that did not received ANS (Kochanek and Hallenbeck, 1992) . Bednar et al. (1991) , after thromboembolic stroke combined with arterial hy potension in rabbits, observed improved CBF, de creased ICP, and a reduction in ischemic lesion size by 4 h as measured by 2,3,5-triphenyltetrazolium chloride (TTC), a marker of mitochondrial oxida tive enzyme function. Interpretation of these stud ies is difficult because arterial hypotension per se may lead to PMNL activation with capillary plug ging by activated cells (Bagge et aI., 1980; Ya makawa et aI., 1987; Barroso-Aranda et aI., 1988) .
A very selective depletion of PMNLs without re duction of other WBC lines in rats has been achieved by Shiga et ai. (1991) and Matsuo et ai. (1994) after intraperitoneal injection of RP-3, a monoclonal antibody (MoAb) developed specifi cally against PMNLs (Table 3) . Depletion of circu lating PMNLs throughout focal cerebral I1R sup pressed postischemic edema formation and signifi cantly reduced the size of the ischemic lesion by TTC at 24 h (Matsuo et aI., 1994) . Matsuo et ai. (1994) demonstrated that tissue PMNL content cor related well with brain edema in nontreated con trols: Both reached a maximum between 24 and 72 h after the insult. Garcia et ai. (l994a) showed a nearly identical time course of PMNL invasion into brain parenchyma in rats with permanent middle cerebral artery occlusion (MCAO) with neutrophils peaking at 24 h.
The findings by Matsuo et a!. (1994) suggest that PMNL invasion after cerebral ischemia was caus ally related to the development of postischemic brain injury. Unfortunately, their study is lacking in quantitative data on true neuronal and microvessel loss. TTC is associated with histochemical abnor malities that represent, under some circumstances, reversible components of cerebral injury that do not always correlate well with histology (Liszozak et a!., 1984; Cole et a\. , 1990) .
Antineoplastic agents
Antineoplastic agents such as mechlorethamine, cyclophosphamide, and vinblastine cause myelo suppression affecting all blood cells and may cause complications such as nausea and vomiting leading to cardiovascular collapse, dehydration, and meta bolic alkalosis (Dutka et aI. , 1989) . Pretreatment of the animals is usually started 3-4 days before the ischemic insult with a 70-90% reduction in neutro phil count (Tables I and 2 ). Most authors report a concomitant decrease in hematocrit (Aspey et aI., 1989; Biagas et aI., 1992) , platelet count (Modha et aI. , 1988; Aspey et aI., 1989; Vasthare et a!. , 1990) , and/or WBC count (Modha et aI. , 1988; Aspey et aI., 1989; Vasthare et aI. , 1990; Helps and Gorman, 1991) .
Antineoplastic agents have been used in models of experimental focal and global cerebral ischemia (Tables I and 2 ), but the observation period has generally been limited to <3 h after the insult. Within this time period, most authors reported an improvement of cerebral parameters such as CBF and evoked potentials (EPs), and in one study (Heinel et a!., 1994) even ischemic injury size (by TTC). These results are partially in accordance with findings by Schiirer et al. (I 990a ) and Grogard et al. (1989) who, in ANS-induced neutropenia, also found evidence for direct WBC involvement during ischemia and early reperfusion. However, I week after the insult, they were unable to detect any ben eficial effect on nerve cell survival (Schiirer et aI., 1991) . This raises the suspicion that, at least in glob al cerebral ischemia, leUkopenia might simply delay the development of the infarct without having any effect on its final size.
All methodological approaches aiming at a reduc tion of WBCs have weaknesses. First, toxic side effects associated with pharmaceutical WBC deple tion frequently do not permit observation periods exceeding a few hours. Second, most attempts to deplete PMNLs cause incomplete neutropenia and significant suppression of other cell lines, which makes it difficult to attribute an observation to PMNL depletion alone. It has been suggested that J Cereb Blood Flow Metab. Vol. 16. No.6, 1996 even small numbers of circulating neutrophils may produce postischemic microvascular dysfunction (Engler and Covell, 1987) . Platelets and mononu clear cells have also been implicated in the etiology of stroke (Strachan et aI., 1992) . It is known, for example, that platelets accumulate in the ischemic brain (Obrenovitch and Hallenbeck, 1985; Del Zoppo et aI. , 1986; Okada et aI., 1994) and that platelet activation can occur in experimental cere bral I1R (del Zoppo, 1994:36) . Together with gran ulocyte activation, this in turn may trigger the re lease of a variety of vasoactive substances respon sible for vasomotor changes and neuronal damage (Moncada and Vane, 1978; Chan et aI. , 1983; Van houtte and Houston, 1985) . Lymphocytes also ac cumulate in ischemic brain (Barcikowska-Litwin et a!., 1987), and in some of the studies cited, lympho cytes were reduced by >50% (Dutka et aI., 1989; Grogaard et aI. , 1989; Vasthare et aI., 1990; Helps and Gorman, 1991) . Strachan et al. (1992) reported significant reduction of ischemic brain edema by rendering rats Iympho-and thrombopenic using whole-body irradiation, without affecting PMNL counts. Finally, a reduction in circulating cell mass, through hemodilutional effects, may per se confer neuroprotection in experimental cerebral ischemia (Fischer and Ames, 1972) .
MODULATION OF PMNLIEC INTERACTION
MoAbs
Adhesion of PMNLs to the endothelium of post capillary venules is recognized as a prerequisite for subsequent emigration into surrounding tissue (Granger and Kubes, 1994a; Springer, 1994) . The 132-integrin CDIl1CD18 has been identified on WBCs and, together with its counterreceptor ICAM-l on ECs, is involved in WBC adherence to stimulated endothelium. Consequently, blocking of these adhesion receptors with specific MoAbs may attenuate WBC margination and emigration (Argen bright et aI., 1991; Kurose et aI., 1994) .
MoAbs used in experimental models of cerebral ischemia include molecules directed against the CDllb and CD18 subunit of the 132-integrin hetero dimer on PMNLs and ICAM-l on ECs (Tables 2  and 3 ). Adhesion molecules are not specific for a certain cell type. The CDllb subunit is shared by monocytes and PMNLs, and CD18 is found on vir tually all WBCs (Springer, 1994) . ICAM-l has been detected on noncerebral vessels and on cerebrovas cular ECs (Fabry et aI., 1992; Wong and Dorovini Zis, 1992; Hess et aI., 1994a,b; Okada et aI., 1994) . It can mediate binding of all WBCs. For interpreta tion of the following studies, it is important to know the specificity, purity, and functional blocking char acteristics of the MoAb under investigation. U nfor tunately, specific epitope mapping has not been car ried out in every case. A dose of 2 mg/kg i.v. of an MoAb directed against the C0 18 epitope, for exam ple, saturated rabbit or baboon PMNL adhesion sites in vivo within minutes (Wallis et aI., 1986; Price et aI., 1987; Mori et aI., 1992) and impaired PMNL adhesion for up to 24 h (Price et aI., 1987; Mileski et aI., 1991) .
The effects of WBC inhibition using MoAbs after focal cerebral ischemia have been studied for up to I week after insult (Tables 2 and 3 ). Support for "capillary plugging" as an important mechanism of WBC-mediated injury comes from a study by Mori et ai. (1992) , who investigated microvascular pa tency in the basal ganglia of baboons after 3 h of MCAO and 1 h of reperfusion as a measure of post ischemic microvascular reflow. Animals receiving the anti-COl8 MoAb IB4 15 min before reperfusion revealed significantly augmented cerebral reflow in noncapillary microvessels up to a caliber of 50 f-lm, which the authors attributed to decreased obstruc tion of these vessels by PMNLs. Of note, and in contrast to other studies employing MoAbs, efforts were made to demonstrate effective binding of MoAb to C0 18 adhesion sites ex vivo (83% satura tion in 5 min).
Experimental studies looking at embolic stroke have yielded controversial results. In microembolic stroke produced by intracarotid injection of micro clots in rabbits, treatment with anti-ICAM-l MoAb was associated with neurological improvement at 24 h only when initiated within 5 min after emboliza tion, but not if infusion was delayed until 180 min after the insult (Bowes et aI., 1993) . Combination with reverse transcriptase plasminogen activator was no more effective than either substance given alone. Clark et al. ( l99 1 a,b) , on the other hand, reported that in irreversible embolic stroke induced by microsphere infusion in rabbits, neither anti ICAM-I nor anti-COl8 MoAb pretreatment im proved neurological function at 18 h. Takeshima et al. (1992) found that in a cat model of 90-min bilateral carotid artery occlusion with uni lateral MCAO and 180-min reperfusion, treatment with anti-COl8 MoAb 60.3 40 min after ischemia did not improve the recovery of somatosensory EPs and did not decrease infarct size. The authors re jected the hypothesis that PMNLs play an impor tant role in transient focal ischemia. However, isch emic insult in this model was severe, producing pro found disturbances of evoked responses with poor recovery after reperfusion and large areas of neu ronal injury. It is possible that the contribution of WBCs to the development of ischemic tissue injury in this model might have been overridden by other factors (Siesjb, 1993) .
The most systematic and careful investigation of WBC-mediated injury has been conducted in rats subjected to permanent or transient (2-h) MCAO followed by 2-7 days of reperfusion (Chen et aI., 1994; Chopp et aI., 1994; Jiang and Chopp, 1994; Zhang et ai., 1994a Zhang et ai., , 1995 Chopp, 1995) . Subjects were treated with different concentrations of either anti-ICAM-I MoAb clone IA29 or anti-COllb MoAb clone 1 B6c upon, or 1-2 h after, reperfusion and a second dose 1 day later (Tables 2-4 ). The volume of ischemic injury was determined from he matoxylin/eosin-stained tissue sections. While the Jiang and Chopp (1994) Anti-CD lIb 2 mg/kg 37" 38" Chopp (1995) Anti-CD lIb 4 mg/kg >40" Anti-CD lIb 4 mg/kg (Fab)2 >40" 4 mg/kg (Fab)2 at 2 h >40" Chen et al. (1994) Anti-CD lIb I mg/kg I3 39 b (cell count) Chen et al. (1994) Anti-CD lib 2 mg/kg 4 3 h 55 b (cell count) Chopp et al. (1994) Anti-CD lib 2 mg/kg 28 h 36/14" (cortex/subcortex; MPO assay) MCAO, middle cerebral artery occlusion; MoAb, monoclonal antibody; WBC, white blood cell; MPO, myeloperoxidase. a p < 0.05, b p < 0.001 VS. carrier-treated control animals.
authors did not report neuroprotection from either antibody in their permanent ischemia model (Table  2) , both antibodies significantly reduced tissue WBC infiltration and infarct size in transient isch emia, even when treatment was delayed up until 2 h after start of reperfusion. An overview of their re sults is given in Table 4 . For example, in the group treated with I mg/kg anti-CDllb at reperfusion, Chen et ai. (1994) observed a 39% reduction of PMNL infiltration, but no significant ischemic le sion reduction. With twice the dose of the same MoAb, however, infarct size as well as PMNL ac cumulation were significantly reduced (43 and 55%, respectively). This was true even when treatment with the same dose was delayed until I h after reperfusion (28 and 36% reduction, respectively) (Chopp et ai., 1994) . These results were also re flected in improved neurological performance of the animals. Measured plasma concentration of free MoAbs was sufficiently high to saturate CD II b re ceptors on circulating WBCs (Chen et aI., 1994), which suggests that other adhesion molecules might also be involved in the PMNL migration pathway. Treatment after 2 h of reperfusion still demon strated an >40% infarct size reduction at 1 week, indicating that treatment did not merely delay the maturation of the ischemic lesion (Chopp, 1995) . Very recently, Chopp (1995) reported the success ful administration of anti-CD 11 b (Fab h fragment MoAb in the same model and with comparable re sults. Treatment with the anti-ICAM-I MoAb upon and at 1 h after reperfusion yielded almost identical results with infarct size reduction of 44% at 1 week postinjury (Zhang et aI., 1994a (Zhang et aI., , 1995 . It will be important to see whether these results can be re produced by other laboratories.
Side effects of antileukocyte interventions with MoAbs
Of all the antineutrophil interventions discussed so far, MoAbs directed against specific adhesion receptor complexes appear to be the most appropri ate candidates for clinical testing. Interference with WBC function, however, might be associated with a variety of adverse effects. Antiadhcsion antibodies are not specific enough to block PMNLs selec tively. The spectrum can be narrowed down to PMNLs and monocytes if the CDII b epitope is cho sen as a target (Springer, 1994) . The role of mono cytes in the setting of cerebral ischemia, however, is still unresolved, and more work is needed to sep arate potentially beneficial effects on tissue repair from destructive processes (Giulian et aI., 1986 (Giulian et aI., , 1989 Olson et aI., 1987; Blight, 1992) . Considering the fact that monocyte invasion into brain tissue J Cereb Blood Flow Metab. Vol. 16. No.6. 1996 begins only after 24 h (Ward et aI., 1988; Garcia et aI., 1993 Garcia et aI., , 1994a , limiting antibody treatment to the first 1-2 days after the insult should avoid this po tential risk. Concerns have also been raised over the application of antiadhesion molecules in pa tients in whom temporary paralysis of WBC func tion might have detrimental effects on host defense (Rosen et aI., 1989; Sharar et aI., 1991) . In in vivo models of bacterial infection, the combination of MoAbs with antibiotics did not show any adverse effects on the severity of infection or on mortality (Tuomanen et aI., 1989; Mileski et al., 1991; Saez Llorens et aI., 1991; Sharar et aI., 1991; Garcia et aI., 1994h) . In two models of bacterial meningitis treatment with anti-CDl8 MoAbs (clone IB4) de creased inflammatory blood-brain barrier damage and attenuated the formation of brain edema (Tuomanen et aI., 1989; Saez-Llorens et aI., 1991) .
In humans, the use of mechanically WBC depleted blood for the prevention of transfusion re actions in sensitized patients has been a well estab lished practice for many years (Hughes and Brozo vic, 1982; Brand, 1994) . The first MoAb approved for human use was' an immunosuppressive agent targeting' lymphocyte antigens for treatment of renal transplant rejection (Russell et aI., 1992) . Since then, experience with MoAbs against WBC adhe sion in humans has been limited to Phase I studies conducted in transplantation patients (Fischer et aI., 1986; Baume et al., 1989; Le Mauff et aI., 1991; Haug et aI., 1993) . Antibodies directed against CDI8, COlla, and ICAM-l in varying concentra tions between 7 and 40 mg/day were used in a total of 43 patients for up to 2 weeks. Minor side effects including chills, nausea, abdominal pain, head aches, and skin rash were encountered, but blood cell counts remained unaffected and no hemolysis occurred. However, one severe fungal infection (Baume et aI., 1989) and one case of pneumonia (Haug et aI., 1993) were observed as well. The safety of antiplatelet murine MoAbs in humans was demonstrated in coronary angioplasty patients treated with the MoAb 7E3 Fab (Ellis et aI., 1993; Tcheng et aI., 1994) .
CONCLUSION
In their review, Kochanek and Hallenbeck (1992) concluded that, as compared to short-lasting global ischemic insults, early PMNL infiltration is "more likely to occur in focal ischemia, which is often pro longed and likely to produce severe tissue injury." In the light of recently published experimental stud ies employing MoAbs to deplete (Shiga et aI., 1991; Matsuo et aI., 1994) or block (Chen et aI., 1994; Chopp et aI., 1994; Zhang et al., 1 994a ; Chopp, 1995; Zhang et aI., 1995) PMNL adherence with high specificity, it seems justified to expand this hypothesis. WBCs clearly contribute to ischemic cell damage in the scenario of experimental focal cerebral ischemia followed by reperfusion, if the ischemic insult is not too severe. However, their role in global ischemia (Aspey et aI., 1989; Schott et aI., 1989; Anderson et aI., 1990) , permanent focal ischemia (Clark et aI., 1991 a, b; Strachan et aI., 1992) , and severe transient focal ischemia (Takeshima et aI., 1992) has not yet been clarified. Based on the literature, it is not possible to identify their target and the impact they have on final patho logical and behavioral outcome.
Global versus focal cerebral ischemia
A critical difference between global cerebral isch emia, on one side, and focal cerebral ischemia, on the other, is the existence of a "penumbra" in the latter, a zone of potentially salvageable cerebral tis sue surrounding the ischemic focus (Astrup et aI., 1981) . Effects produced by antineutrophil interven tions (e.g., a slight increase of CBF) may be suffi cient to ameliorate or prevent cell damage in these borderline regions, whereas conditions in global or forebrain ischemia set rapidly into a state of com plete energy depletion where cells die for other rea sons. As reviewed recently by Siesj6 et al. (1995) , calcium-triggered injury mig�t be the major deter minant in global ischemia.
Transient versus permanent focal cerebral ischemia
The expression of WBC adhesion molecules on ECs appears to be triggered by reperfusion, which might explain the success of antileukocyte strate gies in transient focal cerebral ischemia. In an in vitro study, hypoxia/reoxygenation, but not hypox ia alone, led to an increase of ICAM-l in isolated brain ECs (Hess et at., 1994b) . In permanent focal ischemia or very severe focal cerebral I1R, the con tribution of WBC-mediated injury might be overrid den by other mechanisms of secondary brain dam age. These may include the loss of calcium homeo stasis, leading to activation of protein kinases and new gene expression, free radical-mediated injury, and excessive acidosis (Siesj6, 1993) . Reperfusion of the penumbra in focal cerebral ischemia, on the other hand, allows large numbers of WBCs to reach affected areas and induce tissue damage.
Questions concerning WBCs
The complexity of the pathophysiological prob lem and contradictory results obtained in a great variety of experimental approaches leave many questions unanswered (Hartl, 1995; Kochanek and Hallenbeck, 1992; Schiirer et aI., 1993) :
Correlation between WBC accumulation and tis sue injury in acute cerebral lesions. Few investiga tors have addressed the question of whether there exists a quantitative correlation between WBC ac cumulation/activation or the status of the ECs in ischemic brain parenchyma and parameters of neu rological function before and after blocking/ depleting WBCs. Matsuo et al. (1994) demonstrated that tissue PMNLs after transient focal cerebral ischemia correlated with brain edema in nontreated animals, both reaching a maximum between 24 and 72 h after the insult.
Blocking of WBCs and/or WBC function. If an tileukocyte interventions were employed, the effi cacy of these manipUlations to interfere with WBC function, as characterized by the expression of ad hesion molecules, WBC/EC interaction, tissue infil tration, phagocytosis, chemotaxis, oxygen free rad ical production, and release of cytotoxic metabo lites, has hardly, if ever, been demonstrated. As was pointed out recently by Schmid-Sch6nbein (1993) , documentation of systemic neutropenia af ter employing antileukocyte interventions is not sufficient, because it may merely represent a shift of circulating PMNLs into the marginated pool. Also, most studies focused only on the acute effects after therapy. Therefore, it was not possible to ex clude that a beneficial treatment effect represented merely a transient improvement followed by de layed maturation of the ischemic lesion.
Mechanism of WBC-mediated secondary brain damage. While some studies have demonstrated a positive correlation between WBC accumulation and brain edema formation after cerebral ischemia (Matsuo et aI., 1994) and traumatic brain injury (Schoettle et aI., 1990; Biagas et ai., 1992) , clear-cut evidence as to the mechanism of WBC-mediated injury in the brain has not yet been provided. In this respect, intravital videomicroscopy could offer a powerful tool to shed light on WBC/EC interactions in the cerebral microcirculation. As has been dem onstrated recently by Suematsu et al. (1993 Suematsu et al. ( , 1994 using fluorescent dyes to visualize oxidative stress and irreversible nuclear damage in the rat mesen tery and muscle, intravital videomicroscopy allows the complex interplay between WBCs and func tional changes in endothelial and parenchymal cells to be shown in vivo. It also enables the investigator to control the efficacy and check for potential mi crocirculatory side effects of a particular antileuko cyte intervention. The translation of similar exper iments into the setting of cerebral ischemia and brain injury using closed cranial window prepara-tions may become fruitful in the future. Uhl et al. (1995) have recently reported activation of WBCs in the early reperfusion period after forebrain isch emia in gerbils with intact dura mater and equipped with closed cranial windows. Preliminary results from our laboratory indicate that traumatic brain injury in a chronic cranial window model in rabbits leads to significant WBC activation in postcapillary pia venules as soon as 30 min after insult (Hartl et aI., 1996) .
Evidence against WEe-mediated brain damage.
A role for PMNLs or WBCs in the development of brain damage in the acute phase of cerebral isch emia and brain injury has also been denied (Modha et aI., 1988; Aspey et aI., 1989; Schott et aI., 1989; Anderson et aI., 1990; Schurer et al.. 1990b; Chang et aI., 1992; Takeshima et aI., 1992) . Several inves tigators have reported that lymphocytes, but also PMNLs, might actually confer neuroprotection in early stages of ischemic stroke (Grau et aI., 1994) and after cryogenic brain injury (Schurer et aI., 1990b) .
Summary
Taken together. these experimental results make it worthwhile to further pursue this avenue of re search. Experimental findings strongly suggest that benefits would be more likely in transient focal ce rebral ischemia. This supports the rational clinical testing of rapid reperfusion with effective antileu kocyte strategies. In combination with recent ad vances leading toward a more '"human" MoAb technology and granulocyte adhesion receptor biol ogy with reduced side effects, a number of promis ing strategies may be appropriate (Riechmann et al.. 1988; Clendennin et aI., 1992) . Pharmaceutical ap proaches for the future may also include the use of soluble forms of adhesion molecules (Dana et al.. 1991; Watson et aI., 1991) and (Fabh antibody frag ments. Finally, other forms of acute cerebral disor ders, such as traumatic brain injury, have only be gin to be evaluated in terms of WBC involvement and represent a fertile field for future research (Means and Anderson, 1983; Schoettle et aI., 1990; Biagas et al., 1992; Uhl et al., 1992; Zhuang et al., 1993; Hartl et al., 1996) .
